Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umang Swami

Showing results (91-100 of 170) with videos related to

Pageof 17
Sort By:
European Urology Focus|July 14, 2022
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer SettingNicolas Sayegh, Nishita Tripathi, Roberto H Nussenzveig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2025
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate CancerChadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay, et al.
Biomedicines|December 23, 2022
Detection of <i>BRCA1</i>, and <i>BRCA2</i> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World SettingTaylor Ryan McFarland, Vinay Mathew Thomas, Roberto Nussenzveig, et al.
Molecular Cancer Therapeutics|October 5, 2022
External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate CancerUmang Swami, Nicolas Sayegh, Yeonjung Jo, et al.
Diagnostics (Basel, Switzerland)|September 14, 2024
Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate CarcinomaEmre Dal, Ayana Srivastava, Beverly Chigarira, et al.
Current Medical Research and Opinion|July 23, 2020
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinomaArielle G Bensimon, Yichen Zhong, Umang Swami, et al.
JNCI Cancer Spectrum|November 27, 2025
Socioeconomic position and its effect on cardiovascular outcomes and mortality in patients with prostate cancerTarek Nahle, Omar M Makram, Viraj R Shah, et al.
The Prostate|August 30, 2023
Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancerNishita Tripathi, Vinay Mathew Thomas, Nicolas Sayegh, et al.
European Urology Oncology|April 30, 2025
Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab TrialRohit K Jain, Umang Swami, Mehmet A Bilen, et al.
Human Pathology|January 26, 2024
Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathwayJon Mahlow, Marc Barry, Daniel J Albertson, et al.
Pageof 17

Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
European Urology Focus|July 14, 2022
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer SettingNicolas Sayegh, Nishita Tripathi, Roberto H Nussenzveig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2025
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate CancerChadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay, et al.
Biomedicines|December 23, 2022
Detection of <i>BRCA1</i>, and <i>BRCA2</i> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World SettingTaylor Ryan McFarland, Vinay Mathew Thomas, Roberto Nussenzveig, et al.
Molecular Cancer Therapeutics|October 5, 2022
External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate CancerUmang Swami, Nicolas Sayegh, Yeonjung Jo, et al.
Diagnostics (Basel, Switzerland)|September 14, 2024
Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate CarcinomaEmre Dal, Ayana Srivastava, Beverly Chigarira, et al.
Current Medical Research and Opinion|July 23, 2020
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinomaArielle G Bensimon, Yichen Zhong, Umang Swami, et al.
JNCI Cancer Spectrum|November 27, 2025
Socioeconomic position and its effect on cardiovascular outcomes and mortality in patients with prostate cancerTarek Nahle, Omar M Makram, Viraj R Shah, et al.
The Prostate|August 30, 2023
Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancerNishita Tripathi, Vinay Mathew Thomas, Nicolas Sayegh, et al.
European Urology Oncology|April 30, 2025
Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab TrialRohit K Jain, Umang Swami, Mehmet A Bilen, et al.
Human Pathology|January 26, 2024
Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathwayJon Mahlow, Marc Barry, Daniel J Albertson, et al.
Pageof 17